Monday, November 16, 2026

HLB Panagene Presents Research Findings on Chemical Modifications of PNA at 'OTS 2026'

Input
2026-09-29 11:47:56
Updated
2026-09-29 11:47:56
HLB Panagene CI

[Financial News] HLB Panagene is set to present the therapeutic potential of peptide nucleic acid (PNA), an artificial nucleic acid, at a global nucleic acid therapeutics conference. The company plans to expand its accumulated PNA technology from diagnostics into new drug development and establish the technological foundation needed to develop antibody-oligonucleotide conjugates (AOCs).
HLB Panagene announced on the 29th that it will participate in the 22nd Oligonucleotide Therapeutics Society meeting (OTS 2026), which will be held in Denver, Colorado, from October 11 to 14, and present its research findings on the chemical modification of PNA and splicing regulation in a poster presentation.
The study focused on analyzing how the type and location of chemical modifications introduced into PNA affect splicing regulation. Splicing is the process of connecting the necessary portions of RNA and removing the unnecessary portions before proteins are produced. Regulating this process can induce changes in the proteins that are generated.
The company also plans to apply the findings to its ongoing AOC development efforts. Based on data obtained by optimizing PNA sequences and chemical modifications, HLB Panagene intends to design PNA payloads for conjugation to AOCs and improve their efficacy.
An HLB Panagene official said, "Through this presentation, we will share the competitiveness of our PNA design and chemical modification technologies, as well as their potential for expansion into therapeutics, with researchers worldwide." The official added, "We will build on our accumulated technologies and data to develop PNA-based new drugs and AOC candidates, while also pursuing expanded global partnerships."
[email protected] Choi Doo-sun Reporter